Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
US FDA’s ‘Active Moiety’ Approach On NCE Exclusivity Codified Under Drug Pricing Legislation
Apr 30 2021
•
By
Sue Sutter
Legislative language on 'successor regulations' provides an opening to future changes in the FDA's definition of 'active moiety.'
More from Legislation
More from Pink Sheet